Literature DB >> 18188549

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

Margalida Rotger, Amalio Telenti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18188549     DOI： 10.1007/s00228-007-0440-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

3.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

4.  Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.

Authors:  Carmina R Fumaz; Jose A Muñoz-Moreno; José Moltó; Eugènia Negredo; Maria José Ferrer; Guillem Sirera; Núria Pérez-Alvarez; Guadalupe Gómez; David Burger; Bonaventura Clotet
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-15       Impact factor: 3.731

5.  Efavirenz intoxication due to slow hepatic metabolism.

Authors:  B Hasse; H F Günthard; G Bleiber; M Krause
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

6.  Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

Authors:  David B Clifford; Scott Evans; Yijun Yang; Edward P Acosta; Karl Goodkin; Karen Tashima; David Simpson; David Dorfman; Heather Ribaudo; Roy M Gulick
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

7.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

8.  Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.

Authors:  E L Code; C L Crespi; B W Penman; F J Gonzalez; T K Chang; D J Waxman
Journal:  Drug Metab Dispos       Date:  1997-08       Impact factor: 3.922

9.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079

10.  High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.

Authors:  Christopher Nyakutira; Daniel Röshammar; Emmanuel Chigutsa; Prosper Chonzi; Michael Ashton; Charles Nhachi; Collen Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2007-12-05       Impact factor: 2.953
View more
  7 in total

1.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Authors:  Rubin Lubomirov; Sara Colombo; Julia di Iulio; Bruno Ledergerber; Raquel Martinez; Matthias Cavassini; Bernard Hirschel; Enos Bernasconi; Luigia Elzi; Pietro Vernazza; Hansjakob Furrer; Huldrych F Günthard; Amalio Telenti
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

2.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

Review 3.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.

Authors:  Monica Gandhi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Yong Huang; Kathryn Anastos; Mardge Cohen; Jack A Dehovitz; Gerald B Sharp; Stephen J Gange; Chenglong Liu; Susan C Hanson; Bradley Aouizerat
Journal:  J Infect Dis       Date:  2012-08-20       Impact factor: 5.226

Review 5.  Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.

Authors:  Guillermo Gervasini; Julio Benítez; Juan Antonio Carrillo
Journal:  Eur J Clin Pharmacol       Date:  2010-06-27       Impact factor: 3.064

6.  Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Authors:  Xianmin Meng; Kang Yin; Jiangrong Wang; Ping Dong; Li Liu; Yinzhong Shen; Li Shen; Qing Ma; Hongzhou Lu; Weimin Cai
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

7.  An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Authors:  Marelize Swart; Jonathan Evans; Michelle Skelton; Sandra Castel; Lubbe Wiesner; Peter J Smith; Collet Dandara
Journal:  Front Genet       Date:  2016-01-07       Impact factor: 4.599
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.